Skip to main content

CARLSMED, INC.

For the period ended Sep 30, 2026. Filed Nov 10, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 10, 2026

CARL$14.71-8.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

(in thousands, except share and per share amounts)

Three Months EndedSeptember 30,Nine Months EndedSeptember 30,
2026202520262025
Revenue$21,554$13,074$56,610$35,346
Cost of sales4,8893,14712,9788,914
Gross profit16,6659,92743,63226,432
Operating expenses:
Research and development6,3804,44517,59811,755
Sales and marketing13,0049,61035,22124,218
General and administrative9,9824,90723,82611,715
Total operating expenses29,36618,96276,64547,688
Loss from operations(12,701)(9,035)(33,013)(21,256)
Other income (expense):
Interest expense(316)(380)(940)(1,100)
Interest income7729542,5021,670
Change in fair value of warrant liabilities—(65)—(335)
Total other income (expense), net4565091,562235
Net loss(12,245)(8,526)(31,451)(21,021)
Deemed dividend to preferred stockholders———(584)
Net loss attributable to common stockholders$(12,245)$(8,526)$(31,451)$(21,605)
Net loss$(12,245)$(8,526)$(31,451)$(21,021)
Other comprehensive loss:
Unrealized loss on available-for-sale debt securities(21)—(38)—
Total other comprehensive loss(21)—(38)—
Total comprehensive loss$(12,266)$(8,526)$(31,489)$(21,021)
Net loss per share attributable to common stockholders, basic and diluted$(0.45)$(0.40)$(1.16)$(2.15)
Weighted-average number of common shares used to compute basic and diluted net loss per share27,303,16221,081,33027,104,72910,051,623
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.